Blood Submission Process

ASH's live Blood guidance is stricter than many authors expect in two specific ways.

• Blood requires clinical trials to be registered as a condition of consideration
• the manuscript-preparation guidance expects clear title-page counts and disclosure detail up front
• Blood staff can escalate figure or integrity questions to editors, who may request original data

That means the process is not only a scientific screen. It is also a credibility screen. Papers that look clinically or mechanistically ambitious but operationally loose lose trust earlier here than authors expect.

The administrative layer is familiar:

• main manuscript
• figure files
• supplementary materials
• author information and declarations
• cover letter

The mechanics themselves are not hard, but Blood still forms an early impression from how complete the story appears. If the figures are crowded, the supplement hides critical evidence, or the cover letter is broad and generic, confidence drops before the paper gets serious consideration.

For this journal, the support package matters early because editors often have to judge quickly whether the paper looks like a definitive hematology contribution or a study that still needs another experimental round.

Editors are not asking only whether the biology is interesting. They are asking whether the paper matters to hematology in a way that is obvious from the first page.

That means the manuscript should make these points clear early:

• what hematologic question is being addressed
• what mechanistic or clinical problem is being solved
• why the result matters beyond a narrow sub-question

If the paper reads like general cell biology with blood cells as a convenient model, the process often becomes much harsher.

Blood favors papers that feel finished. Editors often look for:

• mechanistic support rather than correlation alone
• functional validation rather than descriptive observation
• enough scope to feel consequential to the field

If the story still depends on a missing causal experiment or broader validation step, the manuscript feels premature.

This journal is not persuaded by a striking observation alone. The editor usually wants to see:

• appropriate patient, primary-cell, or model evidence where relevant
• functional testing
• coherent figures that build the same story
• controls strong enough to support the main conclusion

The process works best when the editor can see whether the paper belongs with malignant hematology, benign hematology, stem-cell biology, coagulation, immunohematology, or another clear reviewer community.

The route to first decision often slows in a few predictable ways.

This is the most common friction point. Authors may have a strong finding, but the next mechanistic or functional step is still missing.

Editors hesitate when the title and abstract promise broad relevance, but the figures really support a much narrower conclusion.

If the manuscript implies clinical or therapeutic importance without enough evidence to support that framing, trust drops quickly.

If the study sits between hematology, general immunology, oncology, and cell biology without a clear hematology center, reviewer routing becomes slower and more fragile.

Use the journal cluster before you upload:

• Blood journal page
• How to Choose the Right Journal for Your Paper

If the manuscript still feels more like general biology than a hematology paper, the process problem is probably fit, not submission mechanics.

The title, abstract, and first figures should tell the editor:

• what hematologic problem is being addressed
• what the core finding is
• what evidence makes the result believable
• why the result matters to hematology

If those signals are buried, the editor has to infer the case. That is exactly what you do not want.

Blood editors often decide quickly whether the manuscript looks finished. The figures should move from observation to function to consequence in a way that feels complete.

The best supporting package makes the main conclusion easier to trust. If the paper depends on extra validation, additional cohorts, or extended controls, those should be easy to find and interpret.

Your cover letter should explain why this belongs in Blood specifically. State the hematologic question, the strongest mechanistic or clinical consequence, and why the manuscript is stronger than a narrower specialty paper.

Before you submit, ask one practical question: if the editor had two minutes, would they know what hematology question this paper actually settles or materially advances?

For a strong yes, the manuscript should make all of these easy to see:

• the hematologic problem is concrete
• the evidence package supports the conclusion
• the story feels complete enough for a flagship journal
• the consequence matters beyond a narrow corner case
• the reviewer community is obvious

If one of those is still fuzzy, the process becomes slower and more fragile.

• The paper leads with an interesting observation but stops before mechanism or function is convincing.
• The manuscript sounds broader than the figures support.
• The translational significance is asserted too early.
• The supplement contains critical proof that the main paper should have surfaced more clearly.
• The manuscript asks the editor to infer why this matters to hematology.

In our pre-submission review work on Blood submissions, three specific failure patterns create most early stops.

Specific failure pattern: hematology material without a hematology question. Strong immunology or oncology work can still miss Blood if the manuscript reads as adjacent biology rather than as a field-defining hematology paper. Editors routinely screen whether the paper would matter to Blood readers specifically, not just whether blood cells or blood samples appear in the study.

Specific failure pattern: promising mechanism but no causal closure. Blood is much happier with a narrower but finished story than with a broader claim that still needs the decisive causal experiment. In practice, the manuscript slows when the abstract claims a mechanism but the figures still show association, marker movement, or incomplete rescue.

Specific failure pattern: translational consequence pitched faster than the evidence matures. Editors notice quickly when the manuscript wants the clinical implication before it has earned it. This is most exposed in malignant hematology, coagulation, and stem-cell papers where the paper implies treatment relevance but lacks patient-linked validation or functional support.

SciRev author-reported timelines provide a useful community benchmark, but the actionable process question is not only timing. The actionable question is whether the paper gives the editor a clear hematology route, complete evidence package, and credible reviewer community on first read.